For research use only. Not for therapeutic Use.
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion[1].
UK122 (11.1, 33.3, 100 μM; 24 h) dose-dependently inhibits cell migration and significantly reduces the invasiveness of CFPAC-1 cells[1].
UK122 (10-100 μM; 48 h) has no effect of any cell growth or cell morphology change in CFPAC-1 cells[1].
| Catalog Number | I009926 |
| CAS Number | 940290-58-4 |
| Synonyms | 4-[(E)-(5-oxo-2-phenyl-1,3-oxazol-4-ylidene)methyl]benzenecarboximidamide |
| Molecular Formula | C17H13N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H13N3O2/c18-15(19)12-8-6-11(7-9-12)10-14-17(21)22-16(20-14)13-4-2-1-3-5-13/h1-10H,(H3,18,19)/b14-10+ |
| InChIKey | JBHISGPWLXASFE-GXDHUFHOSA-N |
| SMILES | C1=CC=C(C=C1)C2=NC(=CC3=CC=C(C=C3)C(=N)N)C(=O)O2 |
| Reference | [1]. Ming Zhu, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther. 2007 Apr;6(4):1348-56. |
